Gastroesophageal reflux disease (GERD)

HEALTH A–Z

Overview

  • The prevalence of GERD in Asia is low, ranging from 2.5% to 7.1% for weekly reflux, 3.8% to 4.6% for twice weekly reflux, and 2.1% for daily reflux, but it might be due to low awareness of the disorde².
  • The prevalence of symptom-based GERD in Southeast Asia has been rising³ and was estimated to be 6.3%–18.3% from 2005–2010⁴.
  • Left untreated, GERD can result in an esophageal mucosal injury known as reflux esophagitis where persistent backflow of acidic digestive juices will damage the lining of the oesophagus over time⁴.

Symptoms and signs

Heartburn⁶

Vomiting⁶

Burning feeling in stomach or near chest area⁷

Indigestion⁷

Regurgitation⁶

Difficulty swallowing⁶

Chest pain⁷

Causes and risk factors

  • Obesity⁸
  • Hiatal hernia, a condition where the upper part of the stomach moves up into the chest through an opening in the diaphragm, which lowers the pressure in the oesophageal sphincter⁸
  • Stress⁹
  • Certain foods and beverages, such as spicy or fatty foods, chocolate, peppermint, coffee, or alcoholic beverages¹⁰
  • Smoking¹¹
  • Use of certain medications, including calcium channel blockers, painkillers, sedatives, and antidepressants¹²

Supplement recommendations

Fermented soy peptide

Benifits

Symptoms of GERD
It has been shown that fermented soy improved some indicators of heartburn-related quality of life and may have potential benefits for reducing hartburn frequency over time¹³. Studies on gastritis patients have shown that taking a patented food supplement based on non-GMO fermented oy, Gastro-AD® 30 inutes before a meal for 30 days helps in rapid and long-lasting relief within 15 minutes or less ¹⁴,¹⁵. Gastro-AD® not only consisted of fermented soy peptides but also a significant proportion of eat-inactivated Rosell-187 (R0187) strain of lactic acid bacteria. It is shown that R0187 may have a suppressive ffect on interleukin8, the inflammatory cytokine, in intestinal cells¹⁶. This may help with modulating the inflammation response in the mucosal microenvironment and preventing stomach ulcers.

Recommended dosage
Soy protein is most used in daily doses of up to 40-60 grams for 4 months up to 6 months. Gastro-AD® has been tested in several clinical studies, on approximately 600 subjects. It was shown to be tolerable for Gastro-AD® up to 15g per day for 30 days¹⁴. Results show that it provides quick relief from ulcer symptoms including heartburn, pain, vomiting and constipation.

Symptoms of GERD

2g to 5g of Gastro-AD®
, 3 times daily, 30 minutes before meals for 30 days14,15.

Supplement recommendations

Licorice root extract

Mechanism of action

It exerts anti-H. pylori activity by inhibiting protein synthesis, DNA Gyrase, and dihydrofolate reductase17. It also interrupts the inflammatory cascade18 and possesses antioxidant properties¹⁹.

Benifits

Indigestion

Among various gastrointestinal disorders, functional dyspepsia also known as indigestion is one of the most common clinical conditions among the general population. The general symptoms include upper abdominal fullness, epigastric pain, belching, bloating, early satiety, nausea, vomiting, regurgitation, heartburn, and loss of appetite. Oral licorice might improve symptoms of dyspepsia when used in combination with other ingredients.

Meanwhile, a randomised, double-blind, placebo-controlled study showed that deglycyrrhizinated licorice, DGL (GutGard®) helps relieve occasional indigestion²⁰. In the study, the subjects received a specified dose of GutGard® for 15 and 30 days, and the severity of the complaint and quality of life significantly improved compared to the placebo group.

Management of H. pylori

Most people with H. pylori develop chronic gastritis with no symptoms. H. pylori can also cause painful ulcers and gastric cancers3. DGL has also been shown to successfully manage H. pylori. In a 2013 randomised study, participants with H. pylori infection received GutGard® supplementation once daily for 60 days. They are tested before and after supplementation using a stool antigen test (HpSA), and 13C-urea breath test. The result shows promising results over the placebo group whereby participants with GutGard® supplementation tested negative for H. pylori over the placebo group²¹.

Recommended dosage
Licorice extract has been tested in several studies over the years with typical dosages from 100mg up to 1000mg in 1-3 divided dosages for 2-24 weeks. DGL (GutGard®) 150mg either in a separate dose or a single dose for 30 days up to 60 days²⁰,²².

Supplement recommendations

Probiotics

Mechanism of action

Probiotic mechanisms of action include direct interaction with intestinal microbiota to modify its composition, improving gut barrier function and mucosal immunity, reducing mucosal permeability and competitive exclusion which reduces the colonisation of pathogenic bacteria²³,²⁴,²⁵.

Benifits

Gastrointestinal health

Probiotics play an important role in maintaining intestinal microbiota homeostasis and inducing systemic protective responses. It blocks the adherence of pathogens and toxins to the intestinal epithelium by secreting bactericidal substances²⁶. On top of that, probiotics also facilitate short-chain fatty acids production in the gastrointestinal tract which helps to regulate pH and inhibit the activation of NFKB macrophages that can cause inflammatory bowel diseases²⁷. A meta-analysis showed probiotics reduce irritable bowel syndrome and abdominal pain after 8 to 10 weeks of consumption²⁸.

Management of H. pylori

Chronic infection with H. pylori bacteria is a known risk factor for gastric cancer. Probiotic supplementation increases the eradication of H. pylori and reduces the side effect associated with antibiotics and treatment²⁹. Probiotics can inhibit H. pylori growth by secreting SCAFs which results in lowering the pH in gastric lumen and create a competitive condition which inhibits the adherence of pathogen adhesion to mucosal layer²⁹.

Recommended dosage
There is currently no established effective probiotic dosage because it can be affected by species, dose and duration of therapy depending on the clinical indication. The concentration of single strain bacteria is recommended to be >1 billion CFU to ensure effectiveness unless with clinical support³⁰.

Diet & lifestyle recommendations

  • Maintain a healthy weight
  • Have meals at least 2 to 3 hours before lying down³¹
  • Eat smaller portion for each mealtime, avoid overeating³¹
  • Avoid food and beverages that may trigger heartburn, such as fatty meals, citrus fruits and carbonated drinks³¹
  • Sleep on the left side³²

References :

  1. Wu, J. C. (2008). Gastroesophageal reflux disease: An Asian perspective. Journal of Gastroenterology and Hepatology, 23(12), 1785-1793. https://doi.org/10.1111/j.1440-1746.2008.05684.x
  2. Goh, K. (2011). Gastroesophageal reflux disease in Asia: A historical perspective and present challenges. Journal of Gastroenterology and Hepatology, 26, 2-10. https://doi.org/10.1111/j.1440-1746.2010.06534.x
  3. Jung, H. (2011). Epidemiology of gastroesophageal reflux disease in Asia: A systematic review. Journal of Neurogastroenterology and Motility, 17(1), 14-27. https://doi.org/10.5056/jnm.2011.17.1.14
  4. Castell, D. O., & Singh, E. R. (2013). Dysphagia and gastroesophageal reflux disease. Practical Manual of Gastroesophageal Reflux Disease, 239-252. https://doi.org/10.1002/9781118444788.ch14
  5. Batista, A. O., Nascimento, W. V., Cassiani, R. A., Silva, A. C., Alves, L. M., Alves, D. C., & Dantas, R. O. (2020). Prevalence of non-obstructive dysphagia in patients with heartburn and regurgitation. Clinics, 75, e1556.       https://doi.org/10.6061/clinics/ 2020/e1556
  6. Upper digestive tract conditions, symptoms and treatment | Gleneagles hospital Singapore. (n.d.). Private Hospital and Medical Center in Singapore | Gleneagles Hospital. https://www.gleneagles.com.sg/facilities-              services/centre-excellence/ digestive-gut-health/upper-digestive-disorders?gclid=EAIaIQobChMIrZ-ixf2f-AIVyXwrCh3fWg1GEAAYASAAEgJPAfD_BwE
  7. MacFarlane, B. (2018). Management of gastroesophageal reflux disease in adults: A pharmacist’s perspective. Integrated Pharmacy Research and Practice, 7, 41-52. https://doi.org/10.2147/iprp.s142932
  8. Song, E. M., Jung, H., & Jung, J. M. (2012). The association between reflux Esophagitis and psychosocial stress. Digestive Diseases and Sciences, 58(2), 471-477. https://doi.org/10.1007/s10620-012-2377-z
  9. Miller, K. (2008, July 14). Common heartburn triggers. WebMD. https://www.webmd.com/heartburn-gerd/triggersNess-Jensen, E., & Lagergren, J. (2017). Tobacco smoking, alcohol consumption and gastro-                       oesophageal reflux disease. Best Pract Res Clin Gastroenterol, 31(5), 501–508. https://doi.org/10.1016/j.bpg.2017.09.004
  10. Ness-Jensen, E., & Lagergren, J. (2017). Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol, 31(5), 501–508. https://doi.org/10.1016/j.bpg.2017.09.004
  11. GERD: Can certain medications make it worse? (2020, January 22). Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/gerd/expert-answers/heartburn-gerd/faq-20058535
  12. Fatani, A., Vaher, K., Rivero-Mendoza, D., Alabasi, K., & Dahl, W. J. (2020). Fermented soy supplementation improves indicators of quality of life: a randomized, placebo-controlled, double-blind trial in adults experiencing heartburn. BMC research notes, 13(1), 364. https://doi.org/10.1186/s13104-020-05205-z
  13. Bogdanov, I. (1979). Gastropharm–a preparation for treatment of gastritis, gastric and duodenal ulcers. Khranitelna promishlenost.
  14. Hirata, Y. & Uchida, A. (2003) Clinical effects of GASTRO AD for gastritis patients. Japanese Journal of Medicine and Pharmaceutical Science, 49(4), 597-601.
  15. Wallace, T. D., Bradley, S., Buckley, N. D., & Green-Johnson, J. M. (2003). Interactions of lactic acid bacteria with human intestinal epithelial cells: effects on cytokine production. Journal of food protection, 66(3), 466–      472. https://doi.org/10.4315/0362-028x-66.3.466
  16. Dey, S., Deepak, M., Setty, M., D’Souza, P., Agarwal, A., & Sangli, G. K. (2009). Bioactive caffeic acid esters fromGlycyrrhiza glabra. Natural Product Research, 23(18), 1657-1663.                                                            https://doi.org/10.1080/14786410802134348
  17. Chandrasekaran, C., Deepak, H., Thiyagarajan, P., Kathiresan, S., Sangli, G. K., Deepak, M., & Agarwal, A. (2011). Dual inhibitory effect of Glycyrrhiza glabra (GutGard™) on COX and LOX products. Phytomedicine, 18(4), 278-284. https://doi.org/10.1016/j.phymed.2010.08.001
  18. Thiyagarajan, P., Chandrasekaran, C. V., Deepak, H. B., & Agarwal, A. (2011). Modulation of lipopolysaccharide-induced pro-            inflammatory  mediators by an  extract of Glycyrrhiza  glabra and its  phytoconstituents.  Inflammopharmacology, 19 (4), 235-241.https://doi.org/10.1007/s10787-011-0080-x
  19. Raveendra, K. R., Jayachandra, Srinivasa, V., Sushma, K. R., Allan, J. J., Goudar, K. S., Shivaprasad, H. N., Venkateshwarlu, K., Geetharani, P., Sushma, G., & Agarwal, A. (2012). An Extract of Glycyrrhiza glabra            (GutGard) Alleviates Symptoms of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study.   Evidence-based complementary , alternative medicine : eCAM, 2012, 216970.   https://doi.org/10.1155/2012/216970
  20. Schulz, C., Koch, N., Schütte, K., Pieper, D. H., & Malfertheiner, P. (2015). H. pylori and its modulation of gastrointestinal microbiota. J. Dig. Dis., 16(3), 109–117. https://doi.org/10.1111/1751-2980.12233
  21. Puram, S., Suh, H. C., Kim, S. U., Bethapudi, B., Joseph, J. A., Agarwal, A., & Kudiganti, V. (2013). Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study.          Evidence-based complementary andalternative medicine : eCAM, 2013, 263805. https://doi.org/10.1155/2013/263805
DOWNLOAD >>

The material is prepared for informational purposes only and should not be construed as a piece of personal medical advice. Owing to each person’s varying health needs, a physician should be consulted before acting on any information provided in this material. Although every effort is made to ensure that this material is accurate, it is compiled for internal use only and should not be considered definitive. Neither VitaHealth nor its employees, or information providers shall be responsible or liable for any errors, inaccuracies, or other defects in the information contained in this publication.

My Cart
Close Wishlist
Close Recently Viewed
Categories